Studies Underway at TVCC

Studies Underway

There are currently 21 studies underway that include TVCC clients, their families, and/or TVCC staff:

  • Canadian Neuromuscular Disease Registry
    Jan. 2010-Dec. 2022
  • Myoblast transplantation in Duchenne and Becker muscular dystrophy patient
    May 2010-Nov. 2022
  • Capturing the experience of sports-related concussions
    Mar. 2014-Nov. 2022
  • A phase 3, randomized, double blind, sham-procedure controlled study to assess the clinical efficacy and safety of ISIS 396443 administered intrathecally in patients with later-onset spinal muscular atrophy
    Dec. 2014-Ongoing
  • A two-part seamless, multi-center randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of Ro7034067 in type2 and 3 spinal muscular atrophy patients
    Dec. 2016-May 2022
  • Trial readiness and endpoints assessment in congenital myotonic dystrophy
    Dec. 2016-Sept. 2022
  • A double-blind, placebo-controlled, multicenter study with an open-label extension to evaluate the efficacy and safety of SRP-4045 and SRP-4053 in patients with Duchenne Muscular Dystrophy
    Dec. 2016-Jan. 2023
  • Engagement in the pediatric rehabilitation intervention process: Its nature, measurement, and role in the determination of outcomes
    Oct. 2017-Jun. 2022
  • A randomized, double-blind study to evaluate the efficacy and safety to Tideglusib versus placebo for the treatment of children and adolescents with congenital myotonic dystrophy (AMO study)
    Feb. 2018-Mar. 2023
  • Health concerns of adolescents and adults with childhood onset physical disability
    Jun. 2018-Mar. 2023
  • Increasing our knowledge of social and motor skills in children with Autism Spectrum Disorder to help better understand participation in social activities 
    Oct. 2018-May 2022
  • A phase2, two-part multiple-ascending dose study of SRP-5051 for dose determination, then dose expansion, in patients with Duchenne Muscular Dystrophy amenable to Exon 51-skipping treatment
    Jun. 2019-Sept. 2022
  • Escalating dose and randomized controlled study of Nusinersen (BIIB058) in participating with spinal muscular atrophy
    Apr. 2020-Sept. 2022
  • COVID-19 and parents' experiences participating in virtual training to support children's language and social communication development
    Jun. 2020-Nov. 2022
  • Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy
    Oct. 2020-Dec.2022
  • Hearing aid personalization with adolescents: A virtual synchronous focus group study to explore end-user and clinician perspectives
    Mar. 2021-Aug. 2022
  • Fit & Function: Family perspective on fit between education interventions and functional needs for young children with neurodevelopmental disorders
    Jun. 2021-Apr. 2023
  • A phase 3, randomized, double-blind, trial of Pamrevlumab (FG-3019) or placebo in combination with systemic corticosteroids in subjects with non-ambulatory Duchenne muscular dystrophy (DMD)
    Jul. 2021-Jul. 2022
  • A multi-center, longitudinal study of the natural history of subjects with limb girdle muscular  (LGMD) type 2E(LGMD2E/R4), type 2D(LGMD2D/R3), and type 2C(LGMD2C/R5)
    Nov. 2021-Nov. 2022
  • Hearing aid personalization with adolescents: A virtual synchronous focus group study to explore end-user and clinician perspectives
    Aug. 2020-Aug. 2022